IRL receives MPA approval to conduct Phase I trials with IRL790, a novel treatment for complications in Parkinson’s disease

IRL has received approval from Läkemedelsverket (the Swedish MPA) and Regionala Etikprövningsnämnden, EPN, (the ethics committee, Uppsala) to conduct Phase I clinical trials with IRL790. IRL now starts its first Phase I clinical study with IRL790, a psychomotor stabilizer, having potential to alleviate both the adverse motor effects (L-dopa induced dyskinesia, LID) and the adverse psychiatric effects (psychosis) induced by L-dopa in patients with PD. The first Phase I studies are designed to evaluate safety, tolerability and pharmacokinetics.